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Multiple myeloma (MM) t is a malignant neoplasm of differentiated B cells of un-
known etiopathogenesis (1) . While alterations of proto-oncogene loci, including mu-
tations, amplifications, chromosomal translocations, or deletions have been found
associated with several types ofhuman tumors (2), no such association has been
firmly established for MM . In a few MM cases the presence of rearranged (3-5)
or mutated (6)c-myc oncogenes or elevated levels ofc-mycRNA (5) have been reported .
In addition, the simultaneous presence of a c-myc and a N-ras oncogene has been
recently reported in a singleMM cell line (7) . However, these observations remain
as isolated findings that have not been confirmed in studies involving large panels
of cases .
In particular, the frequency of oncoggnnc activation of ras genes has not been es-
tablished in MM . Specific mutations of the H-, K- or N-ras genes are considered
to play a relatively frequent pathogenetic role in tumorigenesis, having been found
in 10-15% ofhuman malignancies (8) . Tumors derived from different tissues display
variations in the frequency, type (H-, K-, or N-) of ras gene and type of mutations
involved . In the specific context oflymphoid malignancies, we recently reported that
significant differences exist among tumors derived from the same tissue since muta-
tions involving the N-ras gene have been found in N20% of acute lymphocytic
leukemia (ALL), whereasno mutations were found innon-Hodgkin lymphoma(NHL)
and chronic lymphocytic leukemia (CLL) (9) .
These considerations prompted us to comprehensively investigate the frequency
ofactivating mutations ofras genes in a relatively large panel ofprimaryMM cases .
In addition, wewanted to conclusively reassess the frequency of c-myc oncogene acti-
vation in this malignancy by determining the frequency of structural alterations of
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the c-myc locus, including rearrangements and mutations. We report here that, while
alterations of the c-myc gene are not detectable at appreciable frequency, mutated
K- or N-ras genes represent a relatively frequent lesion with possible pathogenetic
and prognostic relevance in MM .
Materials and Methods
Pathologic Samples andDNA Preparation.
￿
Pathologic samples from 43 patients at diagnosis
and 13 at clinical relapse were collected during standard diagnostic procedures. Diagnostis
and clinical staging were made according to the criteria described by Durie and Salmon (10).
For evaluation of response to therapy and relapse the criteria established by The SouthWestern
Oncology Group (SWOG) (11) were followed. Mononuclear cell suspensions of >95% via-
bility were prepared from bone marrow aspirates by Ficoll-Hypaque gradient centrifugation.
DNA was purified by digestion with proteinase K, extraction with phenol-chloroform and
precipitation by ethanol (12).
Oligonucleotide Synthesis.
￿
All the oligonucleotides used in this study were synthesized by
the solid-phase triester method (13).
Pblymerase Chain Reaction (PCR).
￿
To amplify sequences spanning 112-115 by across codons
12, 13, or 61 of N-ras and codons 12 or61 of H- and K-ras, we used the panel of oligonucleotide
primers previously described (9). For each PCR reaction, 1 jig of DNA and 20 pmol of each
of the two primers were added to a 50 pl reaction mixture containing 1 U of Taq DNA poly-
merase as previously described (14). 25 cycles of denaturation, annealing and extension (at
94°, 55°, and 72°C, respectively) were performed on an automated heat-block (DNA thermal
cycler; Perkin Elmer Cetus, Norwalk, CT) according to manufacturer's specifications. To
determine the nucleotide sequence within the first exon ofthe c-myc gene, two oligonucleotide
primers [5' primer (sense): GCACTGGAACTTACAACACC; 3' primer (antisense):
GGTGCTTACCTGGTTTTCCA] were used to amplify a 135-bp fragment spanning the
sequences 2738-2871 (15) of the c-myc gene using the same conditions as described above
except for the annealing temperature, which was 67 °C.
Oligonucleotide Hybridization.
￿
Aliquots (2.5 ul) of each PCR mixture were transferred to
replicate nylon filters (Gelman Science,) with a slot blot manifold (Schleicher & Schuell, Keene,
NH) and hybridized sequentially or separately to a panel of 20-men synthetic oligonucleotide
probes identical to these reported by Verlaan-de Vries et al. (16). These probes are represen-
tative of the normal codons 12 and 61 (H-, K-, and N-ras) and codon 13 (N-ras), as well as
ofall the known activating mutations affecting each of these codons. For hybridization, oligo-
nucleotide probes were labeled with .y-[s2P]ATP (specific activity 3,000 Ci/mmol) by means
ofT4-polynucleotide kinase (New England BioLabs, Boston, MA) and separated from unin-
corporated nucleotides through a Bio-Gel P4 fine column (Bio-Rad Laboratories, Richmond,
CA). Prehybridization, hybridization, and washing of filters were performed in a 3 M
tetramethyl ammonium chloride salt solution as described (17).
SequencingofPCR Products.
￿
Direct sequencingof PCRamplified DNA fragments was done
by a modification ofthe protocol originally described by McMahon et al. (18) and latermodified
by Collins (19).
Southern Blot HybridizationAnalysis.
￿
5 kg ofDNA from each sample was digested with the
appropriate restriction endonuclease (Bethesda Research Laboratories, Gaithersburg, MD)
according to manufacturer's specifications, electrophoresed in an 0.8% agarose gel, dena-
tured, neutralized, transferred to nitrocellulose filters, and hybridized according to the method
of Southern (20). DNA probes were "P-labeled by the random priming method (21). After
hybridization filters were washed in 0.2 x SSC/0.5% SDS for 2 h at 60°C and then autoradio-
graphed using intensifying screens (Quanta 111 ; DuPont Co., Wilmington, DE).
DNA Probe.
￿
The organization of the c-myc locus was analyzed by hybridization with a
human c-myc probe, MC413RC, representative of the third exon of the c-myc gene (22).
Results
Analysis of ras Gene Mutations.
￿
56 MM bone marrow aspirates were selected for
this study; 43 samples were obtained at the time of diagnosis (including 1 plasmacell leukemia), and 13 unrelated samples were taken after treatment. All DNAs ex-
tracted from these specimenswere amplified by the PCR method usingpairs of oli-
gonucleotide primers flanking the genomic regions spanning codons 12-13 or 61 of
the H-, K- or N-ras genes (9). Each PCR product was then hybridized to a panel
of synthetic oligonucleotide probes representative of all H-, K- and N-ras mutations
described for human tumors with the exception of mutations in codon 13 of the
K-ras gene (23).
Mutations were detected in 18 of 56 (32%) samples of which 12/43 (27%) were
at diagnosis and 6/13 (46%) were after treatment (see Table I and Fig. 1). Two ras
genes, K- and N-ras, were found to be mutated, although mutation ofthe N-ras gene,
particularly at codon 61, was the most frequent finding. As previously shown for
ALL (9), multiple mutations, sometimes involvingdifferent ras genes, are found in
some MM cases. Note that in two cases contiguous codons of the same gene are
found to be mutated. Since under our experimental conditions an allele containing
two mutations cannot form a stable hybrid with any of the wild-type or single base
pair mutated probes, the two mutations detected in this case must be present in
two distinct alleles.
The lack ofdetectable mutations in the negative cases was not due to insufficient
representation of malignant cells in the samples since all the cases were shown by
histologic examination and Ig gene rearrangement analysis to contain more than
PCL, plasma cell leukemia.
NERI ET AL.
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TABLE I
Summary of ras Oncogene Mutations in MM
Case Stage Ig type ras mutation
Amino acid
substitution
At diagnosis
964 IA GK N-ras 13p2 GGT-GAT GLY-ASP
K-ras 12p2 GGT-GCT GLY-ALA
961 IA Arc N-ras 61p2 CAA-CGA GLN-ARG
963 IA GK N-ras 61p2 CAA-CGA GLN-ARG
978 IIA GK N-ras 61p1 CAA-AAA GLN-LYS
981 IIA GK N-ras 61p1 CAA-AAA GLN-LYS
985 IIA GK N-ras 61p2 CAA-CGA GLN-ARG
980 IIA GK N-ras 61p2 CAA-CTA GLN-LEU
982 IIA GK N-ras 12p2 GGT-GCT GLY-ALA
K-ras 13p1 GGC-AGC GLY-SER
988 IIIA GK N-ras 61pl CAA-AAA GLN-LYS
977 IIIA AK N-ras 61p2 CAA-CGA GLN-ARG
1010 IIIA X N-ras 61pl CAA-AAA GLN-LYS
1011 PCL' AK N-ras 12p1 GGT-TGT GLY-CYS
N-ras 13p1 GGT-TGT GLY-CYS
K-ras 12p1 GGT-TGT GLY-CYS
After treatment
999 IA GK N-ras 13p1 GGT-CGT GLY-ARG
1001 IIA GX N-ras 61p2 CAA-CGA GLN-ARG
1002 IIIA GK N-ras 61p2 CAA-CGA GLN-ARG
1003 IIIA AA N-ras 61p3 CAA-CAC GLN-HYS
1006 IIIA AK K-ras 12p2 GGT-GCT GLY-ALA
1122 IIIA GK K-ras 12pl GGT-CGT GLY-ARG1718
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FIGURE 1 .
￿
Representative da-
taof slot-blot hybridization analy-
sis for mutations of K- and N-ms
codons 12-13 in MM . DNA
fromMM biopsies was ampli-
fied in the region across codons
12-13 ofthe N-ras(A) and K-ras
gene (B), spotted onto a nylon
filter, and hybridized with the
wild-type and mutated probes
as indicated .MMDNAs in A :
la, case 982 ; 2a, 1006 ; 1b, 1011 ;
2b, 1122 . (B) la, case 1122 ; 2a,
1011 ; 3a, 964 ; 4a, 963 ; 5a, 981 ;
16, 980; 26, 985 ; 36, 997 ; 46,
1102 ; 5b, 982 . Note the presence
of two distinct N-ras mutations
in DNA sample 1011 (1b, A).
the 5-10% fraction of malignant cells (not shown) that represents the threshold of
sensitivity of the method under our experimental conditions (9) . It remains pos-
sible, however, that mutations present in a minor subpopulation (<5% of total cells
in the specimen) of malignant cells or mutations different from those described so
far in human tumors, are present in these samples.
To confirm these findings and to determine the exact nature of the mutations,
the nucleotide sequence of the involved regions was determined by direct sequence
analysis ofthePCRproducts (see Table Iand Fig. 2) . The presence of themutations
in the specific codons indicated by the hybridization analysis was confirmed in all
cases, whereas no mutations were detected in the remaining cases within genomic
regions spanning -200 by across codons 12-13 and 61 of the three ras genes. The
presence of two, or in one case (plasma cell leukemia) three, distinct mutationswas
also confirmed . An heterogeneous pattern of mutations was observed, including
different types ofpurine-purine, pyrimidine-pyrimidine, andpurine-pyrimidine tran-
sitions . These changes led to the replacement of glycine or glutamine residues with
one of several different amino acids . No specific difference in the pattern ofmuta-
tions (type of ras gene, codon, or base) is detectable between cases at diagnosis and
after treatment .
Analysis of Clinico-Pathologic Features ofMM Cases Displaying rasMutations.
￿
The het-
erogeneity ofMM cases with respect to the presence of ras oncogenes prompted an
analysis of possible correlations with well-defined clinico-pathologic characteristics
ofMM (10-11) . No correlation was observed between the presence or type of rason-
cogenes at diagnosis and a number of parameters listed in Table II, with the excep-
tion ofa correlation between the presence ofras oncogenes and a partial or complete
lack of response to therapy. Despite the relatively small sample size this correlation
approached statistical significance (p = 0.06).NERI ET AL.
FIGURE 2 .
￿
Direct DNAsequencing ofamplified fragments containing codons 12/13 ofthe K-ras
(A)and N-ras (C) genes and 61 of the N-ms gene (B) in representative normal andMM DNAs .
The 5' or 3' primers used for the in vitro amplification were also used as sequencing primers
(9). Thenormal nucleotide sequences correspond tohuman placentaDNA. Arrows pointto hands
corresponding to mutated base pairs .
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TABLE II
Correlation between Clinical Parameters and Presence of
ras Oncogene Mutations in MM at Diagnosis
Evaluated according to SWOG criteria (11). Response was evaluated after the
first six cycles of therapy.
1 X2 Analysis was applied to these values to test the hypothesis that ras oncogene
mutations are distributed randomly among the three groups. The X2 value cor-
responds top = 0.06.
Analysis ofStructural Alterations o,fthec-mycLocus. Structural alterations ofthe c-myc
locushave been typically found in B cell malignancies carrying chromosomal trans-
locations [(8, 14), (2, 8), and (8, 22)] involving the c-myc gene and Ig loci (24). In
addition, alterations of thec-myc gene have been reported in afew MM casesstudied
that lacked these translocations (3-5). These alterations include: (a) truncations of
the c-myc gene within the first intron, the first exon, or within 5' or 3' flanking se-
quences; (b) mutations of sequences within a specific restricted region of first exon.
The truncations can be detected by Southern blot hybridization of genomic DNA
using restriction enzymes that cut outside c-myc sequences (e.g., Eco RI and Hind
III), while most (60%) of the mutations are detectable as polymorphisms of a Pvu
II site located near the 3' side of exon I (25-26). Recently, by sequencing genomic
DNA amplified by the PCR method, we have demonstrated the presence of c-myc
Parameter No. positive/no. tested
Stage (42 pt.)
IA 3/11
IIA 5/18
IIB 0/2
IIIA 3/10
IIIB 0/1
Percent bone marrow plasma cells (42 pt.)
>10, <30 7/25
>30, <50 2/10
>50 2/7
Protein type (42 pt.)
IgG 9/29
IgA 1/6
Igm 0/1
Light chain 1/6
Hb (g/dl), (42 pt.)
X10 7/28
a8.5, <10 3/11
<8.5 1/3
Bone status index (42 pt.)
0 1/9
1 4/13
2 2/11
3 4/9
Response to therapy' (23 pt.)
Response 0/61
Improvement 3/141
Progression 2/31NERI ET AL .
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FIGURE 3 .
￿
Direct DNA sequencing of a 135-bp fragment spanning the sequences 2387-2871
(15) of the c-myc gene . Representative sequences are shown ofDNAs from normal PBL, from
a Burkittlymphoma biopsy (IM-9) showing a base pair mutation (see arrow), andfrom twoMM
samples (986, 988) . The Pvu II restriction site located at positions 2839-2845 within the first
exon of the c-myc gene (15) is shown as reference point .
mutations in B cell malignancies that carry (8, 14), (2, 8), and (8, 22) translocations
even in those cases where the chromosomal breakpoint is distant (>100 kb) from
the c-myc locus (Murphy, J . P, manuscript in preparation) .
In this report, we have used restriction analysis and nucleotide sequence analysis
ofPCRamplified genomic DNA in order to conclusively assess the frequency of
rearrangements and mutations inMM . No structural alterations were detectable
in a panel of 17 MM cases studied (see Fig . 3 for representative sequencing data) .
This indicates that c-myc activation by currently known mechanisms does not repre-
sent an appreciably frequent event in MM .
Discussion
This report provides the first evidence of an oncogene activation event present
at significant frequency in MM . Previous information on the presence of activated
ras oncogenes in this type of neoplasia hadbeen limited to the report of an activated
N-ras gene in a singleMM cell line (7) and to the report of frequent overexpression
of the H-ras protein without evidence of structural alterations (27) . Several studies
had, however, reported the presence of structural alterations of the c-myc gene in
differentMM cell lines (3-5) . The results of the present study indicate that rear-
rangements of the c-myc locus are not detectable at appreciable frequency in fresh
MM biopsies, suggesting that theymay have occurred during in vitro establishment
ofMM cell lines or that they may have occurred in vivo in a very small number
ofMM cases and possibly contributed to their ability to grow in vitro and thus be
established as cell lines . In addition, mutations of the first c-myc exon analogous to
those found in Burkitt lymphoma were previously detected as restriction enzyme
polymorphisms in 10 of 16 MM biopsies analyzed (6) . These results cannot be1722
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confirmed by our findings, which must be regarded, in this respect, as conclusive
since direct nucleotide sequencing ofthe involved region ofthe c-myc gene has been
performed. In the absence of any detectable structural alterations it remains pos-
sible that increased expression ofthe c-myc gene, perhaps secondary to other genetic
alterations, mayplay a pathogenetic rolein MM, as suggestedby the increased levels
ofc-mycRNA in some MMcases(5). However, this possibility hasnotyetbeen clearly
documented in anyother type oftumorand, in the absence ofclearparameters for
normal levels of c-myc expression, remains speculative.
The mechanism of occurrence of ras oncogene mutations in MM remains un-
known. The pattern of mutations observed in MM appears to confirm towards a
preferential involvement of the N-ras gene in hematopoietic malignancies (28-29).
However, the pattern ofcodon involvement as well as type ofbase and amino acid
substitutions appears significantly moreheterogeneousthan inother hematopoietic
neoplasms (29)and in particular inALL(9). This suggests, amongseveral possibili-
ties, thatthemutationsmaybegenerated throughmultiple and/or relativelynonspecific
mechanisms. Alternatively, itis possible rolethat alarger varietyofmutatedras prod-
ucts are biologically active in the cells that represent the target of transformation
in MM than in ALL.
Regarding the possible role ofras oncogenes in the pathogenesis ofMM it is in-
triguing to note again that ras oncogene mutations display a highly specific pattern
ofdistribution inlymphoid malignancies, astheyare detected atsignificantfrequency
in ALL and MM but are apparently completely absent in NHL and CLL (9). The
difference in the stage ofdifferentiation ofthese tumor types suggests that mutated
ras genes may be biologically active only at early (ALL) orlate (MM) stages oflym-
phoid development. Alternatively, it is possible that the general frequency of point
mutations mayvary during differentstages ofB cell development. Infact, thehighly
mutational environment associated with antigen receptor gene rearrangements and
with the proliferative response following primary antigen stimulation during early
stages ofB cell development has been often suggested as a pathogenetic mechanism
in ALL (30). Analogously, it is possible that the presence ofmutations in MM may
also reflect ananalogous mutational tendency associated with the Iggene rearrange-
ments involved in isotype switching and with the proliferative response following
secondary antigenic stimulation.
We have recentlyshown that the introduction ofactivated H- or N-rasgenescauses
boththe tumorigenicconversion andtheplasmacytoid differentiation ofhumanlym-
phoblastoid cells immortalized by the EBV, leading to the establishmentofcell lines
having morphologic, immunophenotypic, and functional characteristics ofMM cell
lines (31). Although EBVimmortalized cells do not represent the natural target for
ras activation during MM pathogenesis, this experimental model, together with the
results presented here, suggests thatrasoncogenes maycontribute to MM pathogen-
esis by leading toboth themalignant transformation and theplasmacytoid differen-
tiation oftheclonal pre-B-cell populations that are thoughtto represent the precursors
of MM cells (32-34).
Regardless of the mechanisms involved the results presented here indicate that
MM represents an heterogeneous neoplasm with respect to a putative pathogenetic
marker such as the ras oncogene. This heterogeneity prompted us to search for pos-
sibleclinico-prognostic correlates among a variety ofbiological and clinical markersNERI ET AL.
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of MM. Two findings have emerged. First, we found an increased frequency of ras
oncogenes in MM samples obtained after treatment (46% vs. 27% at diagnosis),
suggesting, among several related possibilities, the involvement of ras oncogenes in
later stages oftumorprogressionor the mutageniceffect ofcertainchemotherapeutic
agents. Although of limited value as a single observation, we note also that three
distinct ras mutations were detected in the single case corresponding to the more
advanced and clinically aggressive form of MM, i.e., plasma cell leukemia. Second,
the presence ofras oncogenes at diagnosis correlates with poor therapeutic response.
Although of only indicative statistical significance in this preliminary study, these
correlations have potentially importantclinical implications andwarrant furtherstudies
of larger panels of MM.
Summary
The frequency of ras (H-, K-, and N-ras) and c-myc oncogenes was investigated
in multiple myeloma (MM). By means ofthe polymerase chain reaction (PCR)/oli-
gonucleotide hybridization method, DNA from 56 tumorbiopsies was analyzed for
the presence of activating mutations involving codons 12 and 61 of the H-, K-, and
N-ras genes and codon 13 of the N-ras gene. Mutations, involving the N- or K-ras
genes, were detected in 18 of 56 (32%) cases ofwhich 12/43 (27%) were at diagnosis
and 6/13 (46%) were after treatment. In some cases, multiple mutations affecting
different rasalleles were detected. Direct nucleotide sequence analysis ofPCR prod-
ucts indicatedthat a more heterogeneous nature ofthe base pair changesthan previ-
ously shown for othertumors along with apreferential involvement of N-ras codon
61. The heterogeneity of MM cases with respect to the presence of ras oncogenes
prompted an analysis ofpossible correlations with different clinico-pathologic char-
acteristics of MM from which a correlation between the presence of ras oncogenes
and a partial or complete lack of response to_ therapy emerged. The frequency of
activating rearrangements or mutations of the c-myc gene were studied by Southern
blot analysis andPCR sequencing, respectively. However, contrary to previous reports
involvingmostly MM cell lines, no structural alterations ofthe c-myc gene were found.
Theseresultsindicate that ras, but not c-myc, oncogenes are activated in vivo in MM
cells, representing thefirst oncogene alteration that has been associated at appreciable
frequency with this type of malignancy. While the mechanism of occurrence and
biological role of ras activation in MM remains to be elucidated, the preliminary
correlations observed in this study between the presence of ras oncogenes and poor
therapeutic response suggest that further investigations of the possible prognostic
significance of these alterations are necessary.
Receivedfor publication 20 June 1989.
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